|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 2, March-April 2017
EXPERIENCE OF USE OF PERTUZUMAB IN METASTATIC BREAST CANCER UNDER CLINICAL PRACTICE CONDITIONS
HENAR GARCÍA-LAGUNAR MARÍA, MARTÍNEZ PENELLA MÓNICA, MUÑOZ GARCÍA IRIS, CHARLOTTE VINEY ALICE, CHICA MARCHAL AMELIA MARÍA, MIRA SIRVENT MARÍA CARMEN
Objectives: Pertuzumab is a novel drug with anti-HER2 activity that is authorized in patients with HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel. The aim is to describe the experience of use of pertuzumab under clinical practice conditions.
Method: Retrospective observational study including all patients diagnosed with HER2-positive metastatic breast cancer that started pertuzumab treatment between December 2013 and March 2016. Effectiveness was evaluated by the number of months and cycles of pertuzumab. Safety was assessed by identifying the type and number of adverse effects.
Results: We included 15 women with HER2-positive metastatic breast cancer that have received a median of 18 (IR: 8-31) cycles of pertuzumab for 12.1 (IR: 5.2-22.2) months. Seven women stopped the treatment because of deterioration or disease progression. The remaining eight patients are still being treated with pertuzumab.
Conclusion: Pertuzumab is an effective option with an acceptable toxicity pro-file in HER2-positive first-line metastatic breast cancer.
BREAST NEOPLASM – HER2 – METASTASIS – PERTUZUMAB